PMID- 25512144
OWN - NLM
STAT- MEDLINE
DCOM- 20170110
LR  - 20181113
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Linking)
VI  - 19
IP  - 1
DP  - 2016 Jan
TI  - HER2 testing in paired biopsy and excision specimens of gastric cancer: the 
      reliability of the scoring system and the clinicopathological factors relevant to 
      discordance.
PG  - 176-82
LID - 10.1007/s10120-014-0453-0 [doi]
AB  - BACKGROUND: Inclusion of trastuzumab in chemotherapy regimens is advantageous for 
      patients with advanced or metastatic gastric cancer who overexpress HER2. 
      Therefore, accurate assessment of HER2 status in tumor tissue is critical when 
      weighing treatment options. METHODS: We examined HER2 expression in 180 paired 
      endoscopic biopsy and surgical excision specimens of gastric cancers via 
      immunohistochemistry (IHC). Equivocal IHC results (IHC 2+) were resolved by HER2 
      fluorescence in situ hybridization (FISH). The relationships of several clinical 
      and pathological features with discordant HER2 results in paired specimens were 
      determined. RESULTS: Fourteen biopsy specimens and surgical specimens (7.8%) were 
      HER2-positive. Discordant HER2 IHC scores were observed in 90 paired specimens 
      (50%) and 8 paired specimens (4.4%) had discordant results. The kappa 
      coefficients for an HER2 diagnostic algorithm were 0.264, 0.339, and 0.690 for 
      IHC scores, IHC categories, and final results, respectively (p < 0.001). 
      Discordant HER2 results were significantly associated with discordant tumor 
      differentiation in the paired biopsy and excision specimens (p = 0.01). 
      Intratumoral heterogeneity did not predict HER2 discordance. There was no 
      association between HER2 discordance and the number of biopsy tissue fragments (p 
      = 0.764). CONCLUSIONS: Hofmann's HER2 scoring system is a fairly reliable tool 
      for evaluating HER2 status in biopsy and excision specimens. Discordant HER2 
      results in paired specimens were observed in a small percentage of gastric 
      cancers. Testing all available specimens should be considered in order to 
      eliminate discrepancies, especially when discordant tumor differentiation is 
      observed.
FAU - Huang, Shih-Chiang
AU  - Huang SC
AD  - Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung 
      University, College of Medicine, Taoyuan, Taiwan, ROC.
FAU - Ng, Kwai-Fong
AU  - Ng KF
AD  - Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung 
      University, College of Medicine, Taoyuan, Taiwan, ROC.
FAU - Lee, Shang-En
AU  - Lee SE
AD  - Cancer Diagnostic Laboratory, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
FAU - Chen, Kuang-Hua
AU  - Chen KH
AD  - Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung 
      University, College of Medicine, Taoyuan, Taiwan, ROC.
FAU - Yeh, Ta-Sen
AU  - Yeh TS
AD  - Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, 
      College of Medicine, Taoyuan, Taiwan, ROC.
FAU - Chen, Tse-Ching
AU  - Chen TC
AD  - Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung 
      University, College of Medicine, Taoyuan, Taiwan, ROC. ctc323@cgmh.org.tw.
AD  - Department of Pathology, Chang Gung Memorial Hospital, No. 5 Fuxing St., Guishan 
      Township, Taoyuan County, 333, Taiwan, ROC. ctc323@cgmh.org.tw.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141217
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor
MH  - Biopsy/*methods
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*analysis/genetics/metabolism
MH  - Retrospective Studies
MH  - Stomach Neoplasms/metabolism/*pathology/surgery
OTO - NOTNLM
OT  - Biopsy
OT  - Discordance
OT  - Excision
OT  - Gastric cancer
OT  - HER2
EDAT- 2014/12/17 06:00
MHDA- 2017/01/11 06:00
CRDT- 2014/12/17 06:00
PHST- 2014/07/16 00:00 [received]
PHST- 2014/11/28 00:00 [accepted]
PHST- 2014/12/17 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2017/01/11 06:00 [medline]
AID - 10.1007/s10120-014-0453-0 [pii]
AID - 10.1007/s10120-014-0453-0 [doi]
PST - ppublish
SO  - Gastric Cancer. 2016 Jan;19(1):176-82. doi: 10.1007/s10120-014-0453-0. Epub 2014 
      Dec 17.